Development of bionanocapsules targeting brain tumors

Yumi Tsutsui, Kazuhito Tomizawa, Mana Nagita, Hiroyuki Michiue, Tei ichi Nishiki, Iori Ohmori, Masaharu Seno, Hideki Matsui

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Bionanocapsules (BNCs) are hollow nanoparticles that are composed of L protein (the hepatitis B virus surface antigen) and show specific affinity for human hepatocytes. The pre-S1 peptide displayed on the surface of BNCs is the specific ligand for binding to the receptor on human hepatocytes. Therefore, BNCs are not delivered to other tissues, such as the brain. The aim of the present study was to develop a novel drug delivery system (DDS) targeting brain tumors using BNCs that selectively targeted brain tumors. Epidermal growth factor receptor (EGFR), especially a constitutively active genomic sequence deletion variant of EGFR (EGFRvIII), is overexpressed in human glioblastoma. In the present study, we replaced the pre-S1 peptide with the antibody affinity motif of protein A and made hybrid BNCs conjugated with anti-human EGFR antibody recognizing EGFRvIII. The hybrid BNCs were efficiently delivered to glioma cells but not normal glial cells. Moreover, we confirmed the specific delivery of the hybrid BNCs to brain tumors in an in vivo brain tumor model. These results suggest that this new approach using BNCs is a promising system for brain tumor-targeted drug delivery.

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalJournal of Controlled Release
Volume122
Issue number2
DOIs
Publication statusPublished - Sep 26 2007

Keywords

  • Brain tumor
  • Drug delivery system (DDS)
  • Gene therapy
  • Hepatitis virus B (HBV)

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Development of bionanocapsules targeting brain tumors'. Together they form a unique fingerprint.

  • Cite this